V0499-16
Clone Type
PolyclonalHost
RabbitSource
HumanIsotype
IgGGrade
Affinity PurifiedApplications
WBCrossreactivity
Hu Mk Mo RtGene ID
51231Shipping Temp
Blue IceStorage Temp
-20°CRabbit Anti-Vaccinia Related Kinase 3 (VRK3)
The vaccinia-related kinase (VRK) proteins are a new group of Ser/Thr kinases in the human kinome. This mammalian kinase family comprises three members, VRK1, VRK2, and VRK3 (1-3). The VRK1 has autophosphorylation activity and phosphorylates several transcription factors, including p53 (4), ATF2 (5), and c-Jun (6). VRK2 is associated with the endoplasmic reticulum (7). VRK3 suppresses ERK activity through direct interaction and activation of the MAP kinase phosphatase VHR (8). Further functional and structural analysis of VRK proteins will elucidate important new aspects of cell regulation.
Applications
Suitable for use in Western Blot. Other applications not tested.
Recommended Dilution
Western Blot: 1:1000, incubate membrane with diluted antibody in 5% BSA, 1X TBS, 0.1% Tween-20 at 4°C with gentle shaking, overnight. Optimal dilutions to be determined by the researcher.
Storage and Stability
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Immunogen
Synthetic peptide corresponding to human VRK3. Uniprot Accession: Q8IV63
Form
Supplied as a liquid in 10mM sodium HEPES, pH 7.5, 150mM sodium chloride, 0.1mg/ml BSA, 50% glycerol.
Purity
Purified by Protein A and peptide affinity chromatography.
Specificity
Recognizes endogenous levels of total human VRK3 protein. Species Crossreactivity: monkey, mouse and rat
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
References
(1) Nezu, J. et al. (1997) Genomics 45, 327–31. |(2) Zelko, I. et al. (1998) Arch Biochem Biophys 352, 31–6. |(3) Vega, F.M. et al. (2003) FEBS Lett 544, 176–80. |(4) Lopez-Borges, S. and Lazo, P.A. (2000) Oncogene 19, 3656–64. |(5) Sevilla, A. et al. (2004) J Biol Chem 279, 27458–65. |(6) Sevilla, A. et al. (2004) Oncogene 23, 8950–8. |(7) Nichols, R.J. and Traktman, P. (2004) J Biol Chem 279, 7934–46. |(8) Kang, T.H. and Kim, K.T. (2006) Nat Cell Biol 8, 863–9.USBio References
No references available